GenericStason entered the US generic market in 1994, and currently holds a portfolio of approved ANDAs.
ManufacturingStasons cutting-edge cGMP manufacturing capabilities include facilities from pilot plant and clinical
BrandIn 2008, Stason launched the Brand Division when we acquired exclusive development
WorldwideWe partner with North American & European companies to license products into Asia
Stason offers contract services to drug development companies that need a qualified facility and support staff with capabilities to formulate, optimize and test, clinical trial materials and commercial products.